Case Reports
23 April 2024
Vol. 18 No. 2 (2024)
A rare case of thrombocytopenia secondary to taking febuxostat
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
961
Views
475
Downloads
296
HTML
Authors
A new and powerful selective xanthine oxidase inhibitor called febuxostat seems to be well tolerated by all patient populations, even those who are allopurinol-sensitive. Thrombocytopenia is an extremely uncommon side effect. The case of a 63- year-old man who presented with sudden thrombocytopenia and was ultimately linked to febuxostat consumption is described below. The case happened in our department.
Altmetrics
Downloads
Download data is not yet available.
Citations
Hu M, Tomlinson B. Febuxostat in the management of hyperuricemia and chronic gout: a review. Ther Clin Risk Manag 2008;4:1209-20. DOI: https://doi.org/10.2147/TCRM.S3310
Okamoto K, Eger BT, Nishino T, et al. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem 2003;278:1848-55. DOI: https://doi.org/10.1074/jbc.M208307200
Takano Y, Hase-Aoki K, Horiuchi H, et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/ xanthine dehydrogenase. Life Sci 2005;76:1835-47. DOI: https://doi.org/10.1016/j.lfs.2004.10.031
Okamoto K, Nishino T. Crystal structures of mammalian xanthine oxidoreductase bound with various inhibitors: allopurinol, febuxostat, and FYX-051. J Nippon Med Sch 2008;75:2-3. DOI: https://doi.org/10.1272/jnms.75.2
Osada Y, Tsuchimoto M, Fukushima H, et al. Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents. Eur J Pharmacol 1993;241:183-8. DOI: https://doi.org/10.1016/0014-2999(93)90201-R
Bruce SP. Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. Ann Pharmacother 2006;40:2187-94. DOI: https://doi.org/10.1345/aph.1H121
Mayer MD, Khosravan R, Vernillet L, et al. Pharmacokinetics and pharmacodynamics of febuxostat, a new nonpurine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther 2005;12:22-34. DOI: https://doi.org/10.1097/00045391-200501000-00005
How to Cite
A rare case of thrombocytopenia secondary to taking febuxostat. (2024). Italian Journal of Medicine, 18(2). https://doi.org/10.4081/itjm.2024.1724
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Elisa Eletto, Carmine Siniscalchi, Nicoletta Cerundolo, Beatrice Prati, Lorenzo Finardi, Riccardo Simoni, Alberto Parise, Antonio Nouvenne, Tiziana Meschi, A “cold” case of myxedema coma , Italian Journal of Medicine: Vol. 19 No. 2 (2025)
- Mario Visconti, Autoimmune liver diseases: internist's guide from bench to bedside , Italian Journal of Medicine: Vol. 9 No. 1 (2015)
- Paolo Agostinis, Cathryn Anne Scott, Weber-Christian disease: ultrasound can see it , Italian Journal of Medicine: Vol. 8 No. 1 (2014)
- Rocco Manganelli, Salvatore Iannaccone, Walter De Simone, Primary antiphospholipid syndrome progressing to systemic lupus erythematosus: a case report , Italian Journal of Medicine: Vol. 4 No. 2 (2010)
- Silvia Spoto, Emanuele Valeriani, Sebastiano Costantino, Nosography of systemic inflammatory response syndrome, sepsis, severe sepsis, septic shock, and multiple organ dysfunction syndrome in internal medicine patients , Italian Journal of Medicine: Vol. 9 No. 3 (2015)
- Laura Morbidoni, Diletta Olivari, Gout, hyperuricemia and cardiovascular risk , Italian Journal of Medicine: Vol. 12 No. 3 (2018)
- Filippo Pieralli, Antonio Mancini, Alberto Camaiti, Giancarlo Berni, Carlo Nozzoli, The ability of clinical and laboratory findings to predict in-hospital death in patients with thrombotic thrombocytopenic purpura in an internal and emergency medicine department , Italian Journal of Medicine: Vol. 5 No. 4 (2011)
- Daniela Galimberti, Alessandro Navazio, Carlo Salvarani, Gianluigi Bajocchi, Paolo Dolzani, Elisa Assirelli, Anna M. Casali, Maria C. Leone, Attila M. Pizzini, Mauro Silingardi, Dimitriy Arioli, Lorenzo Morini, Davide Favali, Ido Iori, Possible left endoventricular myxoma in a patient with deep vein thrombosis of the lower limbs: a case report , Italian Journal of Medicine: Vol. 5 No. 3 (2011)
- Elisa Mari, Franco Ricci, Davide Imberti, Massimo Gallerani, Agranulocytosis: an adverse effect of allopurinol treatment , Italian Journal of Medicine: Vol. 5 No. 2 (2011)
- Federico Silvestri, Samantha Pasca, Marco Zaramella, Antonella Labombarda, Andrea Barbi, Mauro Desideri, Paolo Guidi, Adolfo Rogato, Matteo Bergamo, Giovanni Barillari, Safety and efficacy of thromboprophylaxis with fondaparinux in elderly acutely ill medical patients with renal impairment: a retrospective single center study , Italian Journal of Medicine: Vol. 7 No. 4 (2013)
You may also start an advanced similarity search for this article.